La catena delle opzioni mostra i dati chiave delle opzioni azionarie di Scinai Immunotherapeutics a vari prezzi di esercizio e date di scadenza. I trader utilizzano queste informazioni per analizzare potenziali operazioni e valutare il sentiment del mercato per Scinai Immunotherapeutics..

Scinai Immunotherapeutics (NASDAQ:SCNI) Azioni, Catena delle Opzioni

Scinai Immunotherapeutics

Scinai Immunotherapeutics Ltd is a biopharmaceutical company focused on developing, manufacturing and commercializing products for the prevention and treatment of infectious diseases and other illnesses. It has executed eight clinical trials in seven countries, around 12,400 participants in the Phase 3 trial of its vaccine candidate and has built a GMP biologics manufacturing facility for biopharmaceutical products. The company is aiming to develop a pipeline of diversified and commercially viable products and platforms beginning with a nanosized antibody (NanoAb) pipeline.

Scinai Immunotherapeutics Ltd. - American Depositary Shares

Scinai Immunotherapeutics Ltd

Scinai Immunotherapeutics reports H1 results

Scinai Immunotherapeutics (SCNI) has released an update. Scinai Immunotherapeutics Ltd., a biopharmaceutical company, has secured a $2 million inve...

Scinai Secures $2M Investment Boost

Scinai Immunotherapeutics Ltd. (SCNI) Q2 2024 Earnings Call Transcript

Scinai Immunotherapeutics (SCNI) has released an update. Scinai Immunotherapeutics has successfully restructured its loan with the European Investm...

Scinai Immunotherapeutics Restructures Debt, Boosts Equity

Scinai Immunotherapeutics regains compliance with Nasdaq listing rule

Scinai Immunotherapeutics (SCNI) has released an update. Scinai Immunotherapeutics Ltd. has successfully restructured its finances, converting near...

Scinai Immunotherapeutics Back on Track with Nasdaq

Scinai Immunotherapeutics (SCNI) has released an update. Scinai Immunotherapeutics Ltd., a biopharmaceutical company, has restructured a significan...

Scinai Immunotherapeutics Restructures Debt, Eyes Growth

Scinai Immunotherapeutics (SCNI) has released an update. Scinai Immunotherapeutics Ltd. has struck a significant deal, granting exclusive global ri...

Scinai Immunotherapeutics Licenses Global Rights

Scinai Immunotherapeutics (SCNI) has released an update. Scinai Immunotherapeutics is set to hold its Annual General Meeting on November 21, 2024, ...

Scinai Immunotherapeutics to Hold Annual Shareholder Meeting

Scinai Immunotherapeutics (SCNI) has released an update. Scinai Immunotherapeutics Ltd has successfully held its Annual Meeting of Shareholders, se...

Scinai Immunotherapeutics Gains Shareholder Confidence

SCNI

Small Cap

Press Releases

Scinai Immunotherapeutics Announces Positive Regulatory Feedback from the PEI on the path for Phase 1/2a in Plaque Psoriasis with its anti-IL-17 nanoAb

Scinai Announces Signing of Loan Restructuring Agreement with European Investment Bank; Converting Approximately $29 million of Debt to Preferred Equity Convertible into 19.5% Common Equity

Earnings

Scinai Publishes Q2 2024 Financial Results and Provides Business Update; Restructures $29 Million Bank Loan to Equity; On Track to Regain Nasdaq Compliance by August 23

Scinai Announces Entering into $2 Million Private Equity Commitment Agreement with its largest Existing Shareholder

Scinai Announces Closing of Loan Restructuring Agreement with European Investment Bank Converting Approximately $29 million of Debt to Preferred Equity and Leaving Debt Balance of $273,000

Scinai Regains Full Compliance with Nasdaq Listing Requirements

General

IBN Announces Latest Episode of The BioMedWire Podcast featuring Amir Reichman, CEO of Scinai Immunotherapeutics Ltd.

Scinai to Host Online Expert Panel on Plaque Psoriasis Treatment and Intralesional Injections of anti-IL-17A/F VHH Antibodies

Scinai Leadership to Showcase Company's cGMP Biologics CDMO and Innovative I&I pipeline during BIO-Europe 2024

Scinai Publishes Financial Results and Provides Business Update; Shareholders' Equity up from negative $7.3 million as of June 30, 2024, to positive $10 million

Aditxt

Apollomics

Bone Biologics

Cyclacel Pharmaceuticals, Inc. - Common Stock

Cyclacel Pharmaceuticals

Dermata Therapeutics, Inc. - Common Stock

Dermata Therapeutics

Entero Therapeutics

Lipella Pharmaceuticals Inc. - Common Stock

Lipella Pharmaceuticals

Molecular Templates

Matinas Biopharma Holdings, Inc. Common Stock

Matinas BioPharma Hldgs

NuCana

Psyence Biomedical Ltd. - Ordinary Shares

Psyence Biomedical

Phio Pharmaceuticals Corp. - Common Stock

Phio Pharma

Qualigen Therapeutics, Inc. - Common Stock

Qualigen Therapeutics

Quoin Pharmaceuticals, Ltd. - American Depositary Shares

Quoin Pharmaceuticals

Revelation Biosciences, Inc. - Common Stock

Revelation Biosciences

Scorpius Holdings

Shuttle Pharmaceuticals Holdings, Inc. - common stock

Shuttle Pharmaceuticals

Salarius Pharmaceuticals, Inc. - Common Stock

Salarius Pharmaceuticals

Sonnet BioTherapeutics Holdings, Inc. - Common Stock

Sonnet BioTherapeutics

TC BioPharm (Holdings) plc - American Depositary Shares

TC BioPharm (Holdings)

Windtree Therapeutics, Inc. - Common Stock

Windtree Therapeutics

ZyVersa Therapeutics, Inc. - Common Stock

Comments

Scinai Immunotherapeutics

Scinai Immunotherapeutics (SCNI) Opzioni

No option chain data available. Please try again later

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO